Difference in survival and prognosis between malignant tumors of odontogenic origin.

IF 2.2 3区医学 Q2 Dentistry

Journal of Stomatology Oral and Maxillofacial Surgery Pub Date : 2024-11-28 DOI:10.1016/j.jormas.2024.102179

Quentin Hennocq, William Pouillot, Chloé Bertolus, Jean-Philippe Foy

{"title":"Difference in survival and prognosis between malignant tumors of odontogenic origin.","authors":"Quentin Hennocq, William Pouillot, Chloé Bertolus, Jean-Philippe Foy","doi":"10.1016/j.jormas.2024.102179","DOIUrl":null,"url":null,"abstract":"Introduction: The prognosis of metastatic ameloblastoma (METAM), now defined as a benign tumor, and malignant odontogenic tumors (MOT) is poorly studied in the literature. The aim of this study was to determine the prognosis and factors influencing the survival of these patients.Material and methods: Using the SEER database, we retrieved clinical data of patients with malignant tumors of dental origin between 1975 and 2020. They include 3 histological groups: metastatic ameloblastoma (METAM), malignant odontogenic tumors (MOT, including odontogenic carcinoma, odontogenic sarcoma, primary intraosseous carcinoma, and ameloblastic carcinoma) and ameloblastic fibrosarcoma (AFS).Results: On 251 patients, we observed no significant difference in disease-specific survival (DSS) between the three histological groups, with 5-year DSS of 77.4 % (59.9 - 100), 84.0 % (78.7 - 89.7) and 71.1 % (50.7 - 99.7) for METAM, MOT and AFS respectively (p = 0.460). In the MOT group, using a multivariate analysis, surgical treatment appeared to be a protective factor for DSS (HR = 0.483 [0.243 - 0.960], p = 0.038) after taking into account the potential confounding factors mentioned above. No variable significantly influenced DSS in the METAM and AFS group in univariate analysis.Discussion: We found no difference in specific survival between the three histological groups. Although metastatic ameloblastoma was reclassified as a benign tumor by the WHO in 2017, the vital risk for patients remains consequent, and statistically similar to malignant odontogenic tumors.","PeriodicalId":56038,"journal":{"name":"Journal of Stomatology Oral and Maxillofacial Surgery","volume":" ","pages":"102179"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stomatology Oral and Maxillofacial Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jormas.2024.102179","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Dentistry","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The prognosis of metastatic ameloblastoma (METAM), now defined as a benign tumor, and malignant odontogenic tumors (MOT) is poorly studied in the literature. The aim of this study was to determine the prognosis and factors influencing the survival of these patients.

Material and methods: Using the SEER database, we retrieved clinical data of patients with malignant tumors of dental origin between 1975 and 2020. They include 3 histological groups: metastatic ameloblastoma (METAM), malignant odontogenic tumors (MOT, including odontogenic carcinoma, odontogenic sarcoma, primary intraosseous carcinoma, and ameloblastic carcinoma) and ameloblastic fibrosarcoma (AFS).

Results: On 251 patients, we observed no significant difference in disease-specific survival (DSS) between the three histological groups, with 5-year DSS of 77.4 % (59.9 - 100), 84.0 % (78.7 - 89.7) and 71.1 % (50.7 - 99.7) for METAM, MOT and AFS respectively (p = 0.460). In the MOT group, using a multivariate analysis, surgical treatment appeared to be a protective factor for DSS (HR = 0.483 [0.243 - 0.960], p = 0.038) after taking into account the potential confounding factors mentioned above. No variable significantly influenced DSS in the METAM and AFS group in univariate analysis.

Discussion: We found no difference in specific survival between the three histological groups. Although metastatic ameloblastoma was reclassified as a benign tumor by the WHO in 2017, the vital risk for patients remains consequent, and statistically similar to malignant odontogenic tumors.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Stomatology Oral and Maxillofacial Surgery Dentistry-Oral Surgery

CiteScore

2.20

自引率

9.10%

发文量

305

期刊介绍： J Stomatol Oral Maxillofac Surg publishes research papers and techniques - (guest) editorials, original articles, reviews, technical notes, case reports, images, letters to the editor, guidelines - dedicated to enhancing surgical expertise in all fields relevant to oral and maxillofacial surgery: from plastic and reconstructive surgery of the face, oral surgery and medicine, … to dentofacial and maxillofacial orthopedics. Original articles include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses. All manuscripts submitted to the journal are subjected to peer review by international experts, and must: Be written in excellent English, clear and easy to understand, precise and concise; Bring new, interesting, valid information - and improve clinical care or guide future research; Be solely the work of the author(s) stated; Not have been previously published elsewhere and not be under consideration by another journal; Be in accordance with the journal''s Guide for Authors'' instructions: manuscripts that fail to comply with these rules may be returned to the authors without being reviewed. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey Platforms.